Advanced Proteome Therapeutics Stock Today
| APTCF Stock | USD 0.0002 0.00 0.00% |
Performance0 of 100
| Odds Of DistressLess than 31
|
Advanced Proteome is trading at 2.0E-4 as of the 26th of November 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 2.0E-4. Advanced Proteome has about a 31 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Advanced Proteome Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. The company has 41.13 M outstanding shares. More on Advanced Proteome Therapeutics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Advanced Pink Sheet Highlights
| CEO, Pres | Paul Woodward |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Advanced Proteome Therapeutics [APTCF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.47 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Advanced Proteome's market, we take the total number of its shares issued and multiply it by Advanced Proteome's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Advanced Proteome classifies itself under Biotechnology sector and is part of Health Care industry. The entity has 41.13 M outstanding shares.
Advanced Proteome Therapeutics has accumulated about 761.6 K in cash with (693.58 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Advanced Proteome Probability Of Bankruptcy
Ownership AllocationAdvanced Proteome holds a total of 41.13 Million outstanding shares. Advanced Proteome Therapeutics shows 10.53 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Advanced Ownership Details
Advanced Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Advanced Proteome without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
| All Next | Launch Module |
Other Information on Investing in Advanced Pink Sheet
Advanced Proteome financial ratios help investors to determine whether Advanced Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Advanced with respect to the benefits of owning Advanced Proteome security.